Evidence-Based Complementary and Alternative Medicine / 2018 / Article / Tab 5

Research Article

An Herbal Medicine, Yukgunja-Tang is more Effective in a Type of Functional Dyspepsia Categorized by Facial Shape Diagnosis: A Placebo-Controlled, Double-Blind, Randomized Trial

Table 5

Change rate of TDS scale, SDS scale, VAS for overall dyspeptic symptoms, NDI-K, FD-QoL questionnaire, SQDQ, and proportion of responder between treatment and placebo group as subgroup analysis.

Change rate of variables/GroupTreatmentPlaceboP value
(n = 64)(n = 32)

TDS scale0.57 (0.35)0.32 (0.54)0.031
SDS scale0.56 (0.39)0.34 (0.72)0.046
VAS for overall dyspeptic symptoms0.46 (0.32)0.41 (0.28)0.483
NDI-K0.59 (0.39)0.44 (0.49)0.135
FD-QoL questionnaire0.61 (0.35)0.19 (2.20)0.463
SQDQ0.40 (0.34)0.34 (0.36)0.402
Proportion of responder (%)82.574.20.415

TDS: Total Dyspepsia Symptom; SDS: Single Dyspepsia Symptom; VAS: Visual Analogue Scale; NDI-K: Nepean Dyspepsia Index-Korean Version; FD-QoL: Functional Dyspepsia-Related Quality of Life; SQDQ: Spleen Qi Deficiency Questionnaire.
Treatment group includes gallbladder and bladder body groups.
Change rate is defined as the value obtained by subtracting the value of 8 weeks from the value of baseline and dividing it by the value of baseline.
Values were analyzed by Pearson's chi-squared test for categorical variables and independent two-sample t-test as parametric statistical test or Mann–Whitney U test as nonparametric statistical test for continuous variables.
Continuous variables are presented as mean (standard deviation).
P value < 0.05 is regarded as statistically significant.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.